First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and ...

Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion ...

Addressing a CII India Reception on the sidelines of the SelectUSA Investment Summit at National Harbour in Maryland on Monday evening, May 4, US Deputy Undersecretary (Policy and International Trade ...

On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to ...

Organon & Co. recently released its 10-Q report. Organon is a global healthcare company focused on women’s health and general ...

On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co. (NYSE:OGN), a U.S. drugmaker, in an all-cash transaction with an estimated value of ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales ...

Post-Organon deal, ICICI Direct downgraded Sun Pharma to Hold, IIFL adjusted to Add, Investec maintained a Sell rating, while JM Financial stayed at Buy but with a cautious "slower orbit" view on long ...

Shares of Organon & Co surged on Friday after a report that Sun Pharma ceutical Industries plans to increase its binding offer for the women’s healthcare company to $13 billion.

After intense negotiations, Sun Pharma is set to acquire Organon for $11.75 billion, marking a significant milestone for Indian overseas acquisitions. The deal aims to strengthen Sun Pharma's global ...

After a tumultuous run on its own as a public company following its 2021 spinoff from Merck, Organon appears likely to be acquired by Sun Pharmaceutical Industries for $14 per share in cash. The ...

Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy ...